Thursday September 04, 2014
Sales growth: +8%
Marseille, September 4, 2014 - QIAGEN Marseille (Alternext - FR0010626028 - ALIPS), a subsidiary of the QIAGEN Group (previously IPSOGEN) a cancer profiling company that develops, manufactures and markets molecular diagnostic tests for leukemia and cancer, today announced revenues for the first half-year 2014.
Total revenue reached 8.3 M€ compared with 7.6 M€ in the first six months of 2013, an increase of +8% over the same period in 2013.
See press release
distributed by |